VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao

Stock News

11/03

VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.

The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.

The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.

VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1101244851"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101244851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101244851?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101244851","market":"sg","top_or_hot":-1,"title":"VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao","media":"Stock News","content":"<p>VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.</p>\n<p>The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.</p>\n<p>The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.</p>\n<p>VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.</p>\n<p>The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.</p>\n<p>The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.</p>\n<p>VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维升药业-B","start_time":0,"source_url":"","article_id":"1101244851","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101244851","pubTimestamp":1762136899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B","BK1161":"生物科技"},"translate_title":"帕洛培特立帕肽在博鳌完成首个处方，维森制药-B(02561)涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.\nThe drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.\nThe company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.\nVISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}